for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sihuan Pharmaceutical Holdings Group Ltd

0460.HK

Latest Trade

1.07HKD

Change

0.01(+0.94%)

Volume

13,751,000

Today's Range

1.05

 - 

1.09

52 Week Range

1.05

 - 

2.22

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.06
Open
1.06
Volume
13,751,000
3M AVG Volume
244.02
Today's High
1.09
Today's Low
1.05
52 Week High
2.22
52 Week Low
1.05
Shares Out (MIL)
9,465.68
Market Cap (MIL)
10,033.62
Forward P/E
-7.59
Dividend (Yield %)
1.84

Latest Developments

More

Sihuan Pharmaceutical Says Drug Registration Approval Granted For Quetiapine Fumarate Er Tablet

Sihuan Pharmaceutical Holdings Group Ltd Posts HY Revenue Of Rmb1,662.3 Mln

Sihuan Pharma Holdings Group Says Unit, Strides Pharma Global Establish JV

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sihuan Pharmaceutical Holdings Group Ltd

Sihuan Pharmaceutical Holding Group Ltd. is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.

Industry

Biotechnology & Drugs

Contact Info

21/F, Building 2,Zhbng 2000 Bsns Ctr

West Balizhuang

Chaoyang District

+86.755.88609726

http://www.sihuanpharm.com/

Executive Leadership

Fengsheng Che

Executive Chairman of the Board

Weicheng Guo

Chief Executive Officer, Executive Deputy Chairman of the Board

Yiau Chong Choi

Chief Financial Officer, Executive Director, Company Secretary

Zhongxin Jia

Chief Operating Officer, Chairman of the Board of Xuanzhu Pharma

Jionglong Zhang

Chief Investment Officer, Executive Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

3.2K

2017

2.7K

2018

2.9K

2019(E)

3.2K
EPS (CNY)

2016

0.168

2017

0.153

2018

0.171

2019(E)

-0.126
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.74
Price To Book (MRQ)
0.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.25
LT Debt To Equity (MRQ)
0.25
Return on Investment (TTM)
-9.39
Return on Equity (TTM)
-7.53

Latest News

Latest News

BRIEF-Sihuan Pharmaceutical says unit to invest in Pharmadax Foshan

* Hainan Sihuan Pharmaceutical, a unit of co, recently entered into agreements with Pharmadax Inc

BRIEF-Sihuan Pharmaceutical sets up R&D centre in in California

* Sihuan pharmaceutical -set up its United States research and development centre in san francisco bay area in california Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up